Grimes & Company, Inc. Astrazeneca PLC Transaction History

Grimes & Company, Inc.

  • $3.93 Billion
  • Q3 2025

A detailed history of Grimes & Company, Inc. transactions in Astrazeneca PLC stock. As of the latest transaction made, Grimes & Company, Inc. holds 5,238 shares of AZN stock, worth $431,611. This represents 0.01% of its overall portfolio holdings.

Number of Shares
5,238
Previous 5,290 0.98%
Holding current value
$431,611
Previous $369,000 8.67%
% of portfolio
0.01%
Previous 0.01%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 27, 2025
SELL
$68.72 - $82.11 $3,573 - $4,269
-52 Reduced 0.98%
5,238 $401,000
Q2 2025

Jul 22, 2025
BUY
$64.87 - $75.0 $10,054 - $11,625
155 Added 3.02%
5,290 $369,000
Q1 2025

Apr 17, 2025
SELL
$65.37 - $77.96 $16,865 - $20,113
-258 Reduced 4.78%
5,135 $377,000
Q4 2024

Jan 21, 2025
BUY
$63.2 - $79.58 $18,770 - $23,635
297 Added 5.83%
5,393 $353,000
Q3 2024

Oct 22, 2024
SELL
$76.67 - $87.62 $4,753 - $5,432
-62 Reduced 1.2%
5,096 $397,000
Q2 2024

Jul 22, 2024
SELL
$66.81 - $80.83 $4,543 - $5,496
-68 Reduced 1.3%
5,158 $402,000
Q1 2024

Apr 17, 2024
SELL
$61.03 - $69.57 $27,707 - $31,584
-454 Reduced 7.99%
5,226 $354,000
Q4 2023

Jan 24, 2024
SELL
$61.89 - $69.28 $6,065 - $6,789
-98 Reduced 1.7%
5,680 $382,000
Q3 2023

Oct 19, 2023
BUY
$64.85 - $71.7 $3,242 - $3,585
50 Added 0.87%
5,778 $391,000
Q2 2023

Jul 19, 2023
SELL
$69.91 - $75.81 $12,933 - $14,024
-185 Reduced 3.13%
5,728 $409,000
Q1 2023

Apr 20, 2023
SELL
$63.15 - $71.6 $73,127 - $82,912
-1,158 Reduced 16.38%
5,913 $410,000
Q4 2022

Jan 25, 2023
BUY
$54.21 - $70.44 $3,306 - $4,296
61 Added 0.87%
7,071 $0
Q3 2022

Oct 28, 2022
BUY
$53.02 - $135.75 $107,259 - $274,622
2,023 Added 40.57%
7,010 $384,000
Q2 2022

Jul 22, 2022
BUY
$59.26 - $71.14 $2,903 - $3,485
49 Added 0.99%
4,987 $330,000
Q1 2022

May 06, 2022
BUY
$55.72 - $67.12 $2,173 - $2,617
39 Added 0.8%
4,938 $328,000
Q4 2021

Feb 01, 2022
SELL
$54.02 - $63.83 $108 - $127
-2 Reduced 0.04%
4,899 $285,000
Q3 2021

Nov 08, 2021
BUY
$55.56 - $60.79 $3,444 - $3,768
62 Added 1.28%
4,901 $294,000
Q2 2021

Aug 04, 2021
SELL
$48.42 - $60.18 $96,840 - $120,360
-2,000 Reduced 29.24%
4,839 $290,000
Q1 2021

May 12, 2021
BUY
$47.16 - $54.44 $48,103 - $55,528
1,020 Added 17.53%
6,839 $340,000
Q4 2020

Feb 02, 2021
BUY
$48.52 - $58.02 $48,520 - $58,020
1,000 Added 20.75%
5,819 $291,000
Q3 2020

Nov 12, 2020
SELL
$53.07 - $61.1 $53 - $61
-1 Reduced 0.02%
4,819 $264,000
Q2 2020

Jul 31, 2020
SELL
$43.1 - $55.31 $1,034 - $1,327
-24 Reduced 0.5%
4,820 $255,000
Q1 2020

May 05, 2020
SELL
$37.79 - $51.33 $37,525 - $50,970
-993 Reduced 17.01%
4,844 $216,000
Q4 2019

Feb 05, 2020
SELL
$42.46 - $50.46 $1,953 - $2,321
-46 Reduced 0.78%
5,837 $291,000
Q3 2019

Nov 05, 2019
SELL
$40.12 - $45.47 $31,494 - $35,693
-785 Reduced 11.77%
5,883 $262,000
Q2 2019

Jul 30, 2019
SELL
$37.28 - $41.68 $5,405 - $6,043
-145 Reduced 2.13%
6,668 $276,000
Q1 2019

May 02, 2019
SELL
$35.49 - $43.02 $14,054 - $17,035
-396 Reduced 5.49%
6,813 $276,000
Q4 2018

Feb 01, 2019
SELL
$36.86 - $41.49 $43,126 - $48,543
-1,170 Reduced 13.96%
7,209 $274,000
Q3 2018

Nov 09, 2018
SELL
$34.76 - $39.72 $12,166 - $13,902
-350 Reduced 4.01%
8,379 $331,000
Q2 2018

Aug 10, 2018
SELL
$34.55 - $37.05 $73,246 - $78,546
-2,120 Reduced 19.54%
8,729 $307,000
Q1 2018

May 07, 2018
BUY
$32.97 - $36.63 $65,972 - $73,296
2,001 Added 22.62%
10,849 $380,000
Q3 2017

Nov 03, 2017
BUY
$28.96 - $34.0 $256,238 - $300,832
8,848
8,848 $300,000

Others Institutions Holding AZN

# of Institutions
1,449
Shares Held
489M
Call Options Held
7.22M
Put Options Held
2.57M
View Full List

About ASTRAZENECA PLC

AZN Quotes by TradingView
  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $255B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Grimes & Company, Inc. Portfolio

Follow Grimes & Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grimes & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Grimes & Company, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email